HCR 576 Pre-License Inspection & Pre-Approval Inspection
HCR 576 Pre-License Inspection & Pre-Approval Inspection
Our group designed an extensive strategy of a Pre-License Inspection (PLI) and Pre-Approval Inspection (PAI), which are both carried out by the FDA prior to approval of a product or licensing of facilities. The inspections play an important role by ensuring the site is inspection-ready and adheres to the Current Good Manufacturing Practices (CGMP) and is similar to the submitted application (Shah, 2024). Planning was made by internal mock checks to identify possible gaps. All the documents, such as batch records, validation reports, and equipment logs, were updated, indexed, and readily available. Employees were trained on how to relate well with inspectors and how to refer technical issues to specific Subject Matter Experts (SMEs).
The SMEs were found in key domains: quality and regulatory affairs, manufacturing and process control, analytical testing, microbiology and sterility, and engineering facilities. Every SME was ready to explain their processes clearly and with evidence (McMahon, 2024). We also created an organised inspection atmosphere, a front room where we interact with the FDA and a back war room where we stage documents and assist SMEs. Such an arrangement enables prompt action to inspector demands and prevents delays.
FDA will most probably target CGMP compliance, application conformity, assurance of sterility, validation of analytical methods, equipment qualification, data integrity, and facility design (Morris, 2025). We have summarised our drug manufacturing process to identify the important steps, quality control measures and contamination prevention practices. Special attention was paid to sterile operations, which are the most strictly controlled.
The anticipated result of such preparation is a smooth, well-organised inspection, which will show compliance, quality of the product and trustworthiness of the data. With SMEs in place, documented records, and rooms ready to be inspected, we are in a good position to respond to inspection questions and reduce observations (Cacciatore, 2021). The subsequent procedures involve the continuation of preparedness exercises, keeping a watch on the development of an evolving FDA regulation, and the sustainability of the culture of honesty and accountability towards future adherence.
References
Cacciatore, A. (2021). Best Practices for Designing and Building a Pharmaceutical Manufacturing Facility. Partnering for Bio/Pharma Success Supplement, 19-21. https://search.lib.asu.edu/permalink/01ASU_INST/fdcm53/cdi_proquest_reports_2826829490
McMahon, L. (2024, March 14). Pharmaceutical facility design: What to consider. Retrieved from https://standingcloud.com/key-considerations-when-designing-a-pharmaceutical-facility/
Morris, J. (2025, July 7). Pre-Approval Inspection (PAI): What it is and How to Prepare. Pre-Approval Inspection (PAI): What it is and How to Prepare. https://www.propharmagroup.com/thought-leadership/pre-approval-inspection-pai-what-it-is-and-how-to-prepare
Shah, A. (2024, December 7). Understanding the production process of sterile injectables. TSA Process Equipment. https://www.tsaprocessequipments.com/understanding-the-production-process-of-sterile-injectables/
HCR 576 Pre-License Inspection & Pre-Approval Inspection
